Recently, the topic of weight-loss drugs has been extremely popular. Last week, the stock price of Pharmaceutical company Novo Nordisk (NVO) increased by 10% within a week because its weight loss drug Ozempic showed therapeutic effects on chronic kidney failure in diabetic patients during trials.
As public interest in weight loss drugs continues to increase, it may bring some chain reactions to the capital market... Let's take a look at the la...